Detalhe da pesquisa
1.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507690
2.
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
Br J Haematol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720530
3.
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Cancer Discov
; 13(9): 1982-1997, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37249512
4.
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Haematologica
; 101(5): e185-8, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26869629
5.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
J Clin Oncol
; 39(18): 1959-1970, 2021 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739857
6.
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b studyâ.
Leuk Res
; 100: 106489, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33302031
7.
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).
Ann Hematol
; 90(7): 847-9, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20949272